Synthetic Biologics, Inc. (SYN)
EBITDA Growth
74.71%
Quarterly · Period ending:
SYN EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported74.71%period ending
Latest reported74.71%period ending
SYN Quarterly EBITDA YoY % (62.03% → 74.71%)
Year-over-year change
High-resolution chart · PNG
SYN ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| 74.7141% | |
| -7.6923% | |
| -4,143.1373% | |
| -53.5226% | |
| -45.8419% | |
| 15.4187% | |
| -19.2379% | |
| -20.9969% | |
| -25.7622% | |
| -53.208% | |
| -53.8777% | |
| -69.9161% | |
| -152.6721% | |
| -58.7805% | |
| -12.0452% | |
| 13.8679% | |
| 32.6087% | |
| 59.4862% | |
| 18.4385% | |
| 15.7681% | |
| 0.8366% | |
| -40.0111% | |
| 15.8953% | |
| -53.6748% | |
| -206.3291% | |
| 66.7403% | |
| 1.6444% | |
| 19.5052% | |
| 225.5045% | |
| -30.9314% | |
| 25.8919% | |
| 74.195% | |
| 78.7287% | |
| -22.8753% | |
| 58.4043% | |
| 12.4858% | |
| -69.1488% | |
| -37.7243% | |
| -199.0334% | |
| -222.0339% | |
| -53.607% | |
| -46.0393% | |
| -83.1791% | |
| -72.9815% | |
| 65.0407% | |
| -75.0782% | |
| -34.1069% | |
| -87.8814% | |
| -286.7861% | |
| -78.7015% | |
| -11.933% | |
| 43.8842% | |
| -301.7971% | |
| -67.3837% | |
| -254.805% | |
| -111.3625% | |
| 21.9937% | |
| -18.3464% | |
| 236.0823% | |
| 2.3449% | |
| -21.5553% | |
| 59.1315% | |
| 52.921% | |
| 65.9003% | |
| 73.3428% | |
| 35.3748% | |
| 3.6777% | |
| -5.1984% | |
| 24.8536% | |
| -39,234.9485% | |
| -39,618.336% | |
| -450.8831% | |
| -40,734.5% | |
| 152.42% | |
| 1,578.4249% | |
| 1,245.0574% | |
| 604.9481% | |
| 71.2817% | |
| 65.9812% | |
| 48.9266% | |
| -39.0421% | |
| -97.1601% | |
| -88.1932% | |
| -94.3884% | |
| -63.3285% | |
| -8.14% | |
| 87.7459% | |
| 3.4757% | |
| -8.9401% | |
| -35.282% | |
| -1,374.5699% | |
| -27.2727% | |
| -85.7143% | |
| 47.619% | |
| 40% | |
| 38.8889% | |
| 78.7879% | |
| 19.2308% | |
| 28.5714% | |
| -20% |